161 related articles for article (PubMed ID: 15166253)
1. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
Bernier V; Lagacé M; Lonergan M; Arthus MF; Bichet DG; Bouvier M
Mol Endocrinol; 2004 Aug; 18(8):2074-84. PubMed ID: 15166253
[TBL] [Abstract][Full Text] [Related]
2. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M
Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941
[TBL] [Abstract][Full Text] [Related]
4. Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.
Kocan M; See HB; Sampaio NG; Eidne KA; Feldman BJ; Pfleger KD
Mol Endocrinol; 2009 Apr; 23(4):559-71. PubMed ID: 19179480
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
[TBL] [Abstract][Full Text] [Related]
8. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.
Barak LS; Oakley RH; Laporte SA; Caron MG
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):93-8. PubMed ID: 11134505
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor.
Hawtin SR
J Biol Chem; 2006 May; 281(21):14604-14. PubMed ID: 16565083
[TBL] [Abstract][Full Text] [Related]
10. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
Robben JH; Sze M; Knoers NV; Deen PM
Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
[TBL] [Abstract][Full Text] [Related]
11. Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors.
Wilbanks AM; Laporte SA; Bohn LM; Barak LS; Caron MG
Biochemistry; 2002 Oct; 41(40):11981-9. PubMed ID: 12356298
[TBL] [Abstract][Full Text] [Related]
12. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
[TBL] [Abstract][Full Text] [Related]
13. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
Tan CM; Nickols HH; Limbird LE
J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins.
Erdem Tuncdemir B; Mergen H; Saglar Ozer E
Eur J Pharmacol; 2019 Dec; 865():172803. PubMed ID: 31738937
[TBL] [Abstract][Full Text] [Related]
16. Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.
Erdélyi LS; Mann WA; Morris-Rosendahl DJ; Groß U; Nagel M; Várnai P; Balla A; Hunyady L
Kidney Int; 2015 Nov; 88(5):1070-8. PubMed ID: 26131744
[TBL] [Abstract][Full Text] [Related]
17. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
18. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns.
Terrillon S; Barberis C; Bouvier M
Proc Natl Acad Sci U S A; 2004 Feb; 101(6):1548-53. PubMed ID: 14757828
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.
Gitelman SE; Feldman BJ; Rosenthal SM
Am J Med; 2006 Jul; 119(7 Suppl 1):S54-8. PubMed ID: 16843086
[TBL] [Abstract][Full Text] [Related]
20. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
